Key Highlights

  • Third-quarter 2026 net sales were USD 2.2 million, against USD 2.2 million a year earlier.
  • Gross Margin was 70% in the quarter, against 65% in the prior-year quarter.
  • Pediatric net sales increased 20% in the third quarter and 26% year to date.
  • Cash and cash equivalents were approximately USD 8.3 million at September 30, 2026.

Nuwellis (NASDAQ:NUWE) reported third-quarter 2026 net sales of USD 2.21 million, against an estimate of USD 2.50 million. Loss per share was USD 5.81, against an estimate of USD 122.85. The company sells the Aquadex system, which is used for fluid removal and kidney support, including in pediatric patients.

Management said third-quarter gross margin expanded 430 basis points, while operating expenses declined 13% year over year, giving a 24% improvement in operating loss.

Sales and Margin

Net sales were USD 2,212 thousand for the three months ended September 30, 2026, against USD 2,217 thousand, a change of 0.2%. For the nine months, net sales were USD 6,584 thousand, against USD 5,846 thousand, an increase of USD 738 thousand, or 12.6%. The filing says Revenue is generated mainly from the sale of consoles and of blood filters and catheters used with the Aquadex consoles.

Management said revenue for the first nine months was USD 6.6 million, an increase of 13%, driven by growth in U.S. circuit and console sales. In the first nine months of 2026 the company sold 32 consoles, against 17 in the prior-year period, an increase of 88%. Pediatric net sales increased 20% in the third quarter and 26% for the nine months.

Gross profit for the third quarter was approximately USD 1.5 million, a gross margin of 70%, against 65% in the prior-year quarter. Operating expenses were approximately USD 3.6 million, against approximately USD 4.1 million a year earlier and approximately USD 4.7 million in the second quarter of 2026. Operating loss moved from approximately USD 2.7 million to USD 2.1 million. Reported net loss for the third quarter was approximately USD 2 million, against Net Income of approximately USD 0.5 million in the prior-year quarter.

Cash and Financing

As of September 30, 2026, the company had cash and cash equivalents of approximately USD 8.3 million, which management said provides runway through the second quarter of next year. In the third quarter, it raised USD 3.4 million in gross proceeds through a registered direct offering in July and received USD 3.3 million in gross proceeds from the cash exercise of warrants. It also received USD 1.4 million in net proceeds from common shares sold under its at-the-market program.

The filing says the company sold 134,488 shares under the at-the-market program during the third quarter for net proceeds of approximately USD 1.4 million. Net cash provided by financing activities was USD 16.8 million for the nine months, primarily from the January 2026 PIPE warrants, the January 2026 Warrant inducement, the June 2026 financing, the July 2026 financing and completion of the September 2025 at-the-market agreement.

Inventories were USD 1,770 thousand at September 30, 2026, against USD 1,910 thousand at December 31, 2025. They included finished goods of USD 698 thousand, work in process of USD 180 thousand and raw materials of USD 969 thousand, less inventory reserves of USD 77 thousand.

Pediatric Evidence and Pipeline

Management cited the ULTRA-Peds Registry, a multicenter study titled Kidney Support in Infants and Children Using Aquadex, accepted for publication in Pediatric Nephrology. The study evaluated 91 pediatric patients treated with Aquadex across seven children's hospitals, with 62% of the patients weighing less than 10 kilograms. The company has also submitted a 510(k) seeking expanded indications for the Aquadex in patients weighing as little as 5 kilograms.

On product development, management said it is advancing SmartView and Pressure IQ, with launches slated for 2027, and Pressure IQ in the first half of 2027. It said development of Clarity Prime, an automated kidney function monitoring technology acquired through Rendiatech, continues. Management said its financial priorities are increasing recurring circuit revenue, reducing cash utilization and directing Capital toward commercial and development programs.